Drug Trial Radar · NCT05789589
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
46
Planned (sponsor's estimate)
Start
Nov 17, 2023
Primary completion
Mar 16, 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Baptist Health South FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Miami Cancer Institute; Cantex Pharmaceuticals Inc.
- First posted
- Mar 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
Conditions
- Cancer
- Metastasis
- Metastatic Cancer
- Brain Metastases
- Brain Metastases, Adult
Interventions
AzeliragonDrug
Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years. All doses are taken orally. There are three levels of dosing, including a starting dose and two lower levels of dosing. Participants will start with the starting dose, and in the event of the dose limiting toxicities, the dose will be reduced as described below. Starting Dose Level: 30 mg twice daily (Loading Dose) or 20 mg once daily (Continuous Dose) Dose Level -1: 15 mg twice daily (Loading Dose) or 10 mg once daily (Continuous Dose) Dose Level -2: 15 mg once daily (Loading Dose) or 5 mg once daily (Continuous Dose)
Stereotactic radiosurgeryRadiation
Patients will undergo standard of care SRS as per the treating facility's policies.
CorticosteroidDrug
Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT). LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Dose-Limiting Toxicities (DLTs)Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.